Nicolas Girard, MD, discusses results from the PALOMA-2 trial which assessed the efficacy and safety of first-line subcutaneous amivantamab, administered once every 4 weeks, plus lazertinib among patients with EGFR-mutated non-small cell lung...
Nicolas Girard, MD, discusses results from the PALOMA-2 trial which assessed the efficacy and safety of first-line subcutaneous amivantamab, administered once every 4 weeks, plus lazertinib among patients with EGFR-mutated non-small cell lung...
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that continuing pemetrexed maintenance therapy is advantageous for patients treated with the KEYNOTE-189 regimen.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that continuing pemetrexed maintenance therapy is advantageous for patients treated with the KEYNOTE-189 regimen.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
Joshua Sabari, MD, discussed exploratory analysis results from the phase 3 MARIPOSA study evaluating the impact of amivantamab dose interruptions, as presented at the European Lung Cancer Congress 2024.
Joshua Sabari, MD, discussed exploratory analysis results from the phase 3 MARIPOSA study evaluating the impact of amivantamab dose interruptions, as presented at the European Lung Cancer Congress 2024.
Alexander Spira, MD, PhD, FACP, discussed post-progression results from the phase 3 MARIPOSA-2 trial, as presented at the European Lung Cancer Congress 2024.
Alexander Spira, MD, PhD, FACP, discussed post-progression results from the phase 3 MARIPOSA-2 trial, as presented at the European Lung Cancer Congress 2024.
Joshua Sabari, MD, discussed post-progression secondary end points from the phase 3 PAPILLON trial evaluating amivantamab plus chemotherapy among patients with advanced EGFR-mutated non-small cell lung cancer, as presented at the European...
Joshua Sabari, MD, discussed post-progression secondary end points from the phase 3 PAPILLON trial evaluating amivantamab plus chemotherapy among patients with advanced EGFR-mutated non-small cell lung cancer, as presented at the European...
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
